Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedPal AILSE:MPAL -4.76% Cash-to-Debt is 0.01 as of Feb. 2026, which is 100% below its 10-year median of 5,000.00. The stock has 1 warning sign investors should review. Among 673 Healthcare Providers & Services companies, MedPal AI ranks worse than 98.22% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MedPal AI's cash to debt ratio for the quarter that ended in Feb. 2026 was 0.01.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, MedPal AIcouldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for MedPal AI's Cash-to-Debt or its related term are showing as below:
LSE:MPAL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 5000 Max: No Debt
Current: 0.01
During the past 4 years, MedPal AI's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 5000.00.
LSE:MPAL's Cash-to-Debt is ranked worse than 98.22% of 673
companies
in the Healthcare Providers & Services industry
Industry Median: 0.78
vs LSE:MPAL: 0.01
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MedPal AI Cash-to-Debt Related Terms
MedPal AI Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for MedPal AI's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MedPal AI Cash-to-Debt Chart
MedPal AI Annual Data
Trend
Aug22
Aug23
Aug24
Aug25
Cash-to-Debt
-
-
-
-
MedPal AI Semi-Annual Data
Feb24
Aug24
Feb25
Aug25
Feb26
Cash-to-Debt
-
-
-
-
0.01
LSE:MPAL vs VEEV, BTSG, TEM: Cash-to-Debt Comparison
For the Health Information Services subindustry, MedPal AI's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedPal AI Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedPal AI's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MedPal AI's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedPal AI (LSE:MPAL) has a Cash-to-Debt of 0.01 as of Feb. 2026. This is 100% below median its historical median of 5,000.00. Over the past decade, MedPal AI's Cash-to-Debt has ranged from 0.01 to 10,000.00. According to the industry distribution chart, MedPal AI ranks #661 out of 673 companies in the Healthcare Providers & Services industry, placing it in the top 98.2%.
Is MedPal AI's Cash-to-Debt too high?
MedPal AI's current Cash-to-Debt of 0.01 is 100% below median its 10-year median of 5,000.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 10,000.00. The Healthcare Providers & Services industry median Cash-to-Debt is 0.78. MedPal AI's value of 0.01 is 98.7% below this industry median. Based on the distribution chart, MedPal AI ranks #661 out of 673 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does MedPal AI's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedPal AI ranks #661 out of 673 companies for Cash-to-Debt. This places MedPal AI in the lower half of its industry. The industry median Cash-to-Debt is 0.78. MedPal AI's value of 0.01 is 98.7% below this benchmark. Historically, MedPal AI's own Cash-to-Debt has ranged from 0.01 to 10,000.00 over the past decade. While the company's 10-year median is 5,000.00 vs. the industry median of 0.78, MedPal AI has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.78, based on 673 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedPal AI's current Cash-to-Debt of 0.01 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedPal AI's current Cash-to-Debt is 0.01, which is 100% below median its own 10-year median of 5,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedPal AI stock overvalued right now?
MedPal AI (LSE:MPAL) has a current Cash-to-Debt of 0.01. The current Cash-to-Debt is 0.01, which is 100% below median its 10-year median of 5,000.00 and 98.7% below the Healthcare Providers & Services industry median of 0.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MedPal AI (LSE:MPAL), the current Cash-to-Debt is 0.01 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MedPal AI PLC is a UK-based digital health and artificial intelligence company focused on the development and commercialisation of AI-enabled healthcare platforms.. Its platform aggregates data across devices and apps (including Apple Health, Fitbit, Garmin, and Google Fit) to deliver real-time, personalized health insights. The Company has two reportable segments, Software and Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:MPAL has been successfully added to your 
